SML0036
Procarbazine hydrochloride
≥98% (HPLC)
别名:
N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H19N3O·HCl
化学文摘社编号:
分子量:
257.76
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
206-678-6
MDL number:
产品名称
Procarbazine hydrochloride, ≥98% (HPLC)
InChI key
DERJYEZSLHIUKF-UHFFFAOYSA-N
InChI
1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
SMILES string
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥18 mg/mL
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.
Biochem/physiol Actions
Procarbazine hydrochloride is a Antineoplastic alkylating agent
Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Soichiro Shibui et al.
Cancer chemotherapy and pharmacology, 71(2), 511-521 (2012-12-12)
Glioblastoma (GBM) is one of the worst cancers in terms of prognosis. Standard therapy consists of resection with concomitant chemoradiotherapy. Resistance to nimustine hydrochloride (ACNU), an alkylating agent, has been linked to methylguanine DNA methyltransferase (MGMT). Daily administration of procarbazine
Eighth Annual Report on Carcinogens, 181-181 (1999)
eIF2alpha phosphorylation is pathognomonic for immunogenic cell death
Bezu L, et al.
Cell Death and Differentiation, 1-1 (2018)
[Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia].
N N Sharkunov et al.
Terapevticheskii arkhiv, 84(11), 71-74 (2012-12-21)
To treat patients with different concurrent cancers, including lympho- and myeloproliferative neoplasms, is a difficult task. The paper presents the experience in successfully treating lymphogranulomatosis occurring in a female patient with chronic myeloid leukemia (CML). A combination of the BEACOPP-14
Wojciech Jurczak et al.
Przeglad lekarski, 69(5), 171-175 (2012-10-12)
Hodgkin Disease is one of the common lymphoma subtypes: every year over 750 new cases are diagnosed in Poland. It is most frequent in young adults between 25 - 30 years of age. In a low risk cases prognosis is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持